Growth Hormone Secretion
Ipamorelin
NNC 26-0161
Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist
This Ipamorelin entry draws on 9 cited sources published 1998 to 2026. The evidence available is graded Anecdotal + Phase 2 on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist
- Drug class
- Growth Hormone Secretion
- Structure
- Pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Route
- SC injection
- Half-life
- ~2 hrs
- Evidence tier
- Anecdotal + Phase 2
- Availability
- Compounding Restricted
- Research depth
- 64 indexed citations →
Mechanism of action
Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise
Reported areas of research
Clean GH release without cortisol/prolactin rise; minimal hunger; lean mass; recovery
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC)
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical
Compared with
Ipamorelin has published head-to-head comparisons with 10 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
Frequently asked questions
What dosing is reported for Ipamorelin in research literature?
Published peptide research reports the following dosing approach for Ipamorelin: 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC). This is a research reference, not a clinical recommendation.
How is Ipamorelin administered in research?
Ipamorelin is administered via the following routes in published studies: SC injection.
What is the reported half-life of Ipamorelin?
The reported half-life of Ipamorelin is ~2 hrs.
Is Ipamorelin FDA-approved?
No. Ipamorelin is not an FDA-approved drug. FDA has placed Ipamorelin in category 2 of its interim policy on compounding with bulk drug substances (503B list, added September 29, 2023), the category of substances FDA considers may present significant safety risks. Ipamorelin was nominated for FDA's bulk drug substance lists, flagged by FDA for possible safety risks, and the nomination was then withdrawn by the party that filed it, which leaves it with no route to lawful compounding rather than with a clean record. PeptideHelper.org catalog status: Compounding Restricted.
Sources: FDA: bulk drug substances that may present significant safety risks.
What level of evidence supports Ipamorelin?
The current evidence base for Ipamorelin is best characterised as: Anecdotal + Phase 2. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Ipamorelin?
Known concerns reported in the literature for Ipamorelin include: Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical. Always consult a qualified clinician before any human use.
Is there anyone who should not use Ipamorelin?
No formal contraindications are established for Ipamorelin, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical. Always consult a qualified clinician before any human use.
How does Ipamorelin work?
The mechanism of action reported for Ipamorelin in the literature: Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise.
What is Ipamorelin studied for?
Ipamorelin has been studied in the published literature for: Clean GH release without cortisol/prolactin rise; minimal hunger; lean mass; recovery. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Ipamorelin?
Ipamorelin is classified as: Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist. Also known as: NNC 26-0161.
Studied in combination
Ipamorelin appears in the following peptide combinations discussed in research and practitioner literature:
- Gold Standard GH, GH pulse amplification
- Fat Loss GH, Visceral fat reduction + GH pulse
Combinations to avoid
Ipamorelin appears in 2 flagged combinations catalogued on PeptideHelper.org:
- Two GHRPs in the same regimen, Moderate risk per peptide research literature.
- GH secretagogues combined with exogenous HGH, Moderate-High risk per peptide research literature.
Drug class
- GHRP peptides, see all peptides tagged GHRP.
- GH-secretagogue peptides, see all peptides tagged GH-secretagogue.
Research focus area
All peptides studied for Growth Hormone Secretion, ranked by evidence tier and regulatory status.
Primary sources
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
- Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in endocrinology 2026. PMID 42395176
- Coutinho LFD et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness 2026. PMID 41880199
- Trifecta Research Study [NCT07717866 ACTIVE_NOT_RECRUITING]
- Villegas Meza AD et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS reviews 2026. PMID 42160466
- Renke G et al. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. International journal of molecular sciences 2026. PMID 42123471
- Mavrych V et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in aging 2026. PMID 42021992
- Tewari K et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American journal of sports medicine 2026. PMID 42578445
- Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.) 2026. PMID 41966639
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…